[go: up one dir, main page]

ZA200203762B - 4-pyridinyl-IN-acyl-L-phenylalanines. - Google Patents

4-pyridinyl-IN-acyl-L-phenylalanines.

Info

Publication number
ZA200203762B
ZA200203762B ZA200203762A ZA200203762A ZA200203762B ZA 200203762 B ZA200203762 B ZA 200203762B ZA 200203762 A ZA200203762 A ZA 200203762A ZA 200203762 A ZA200203762 A ZA 200203762A ZA 200203762 B ZA200203762 B ZA 200203762B
Authority
ZA
South Africa
Prior art keywords
phenylalanines
pyridinyl
acyl
Prior art date
Application number
ZA200203762A
Other languages
English (en)
Inventor
Gerald Lewis Kaplan
Achyutharao Sidduri
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200203762B publication Critical patent/ZA200203762B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
ZA200203762A 1999-12-06 2002-05-10 4-pyridinyl-IN-acyl-L-phenylalanines. ZA200203762B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16909099P 1999-12-06 1999-12-06

Publications (1)

Publication Number Publication Date
ZA200203762B true ZA200203762B (en) 2004-01-28

Family

ID=22614226

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203762A ZA200203762B (en) 1999-12-06 2002-05-10 4-pyridinyl-IN-acyl-L-phenylalanines.

Country Status (33)

Country Link
EP (1) EP1244625B1 (zh)
JP (2) JP2003516392A (zh)
KR (1) KR100492111B1 (zh)
CN (1) CN1196682C (zh)
AR (1) AR031083A1 (zh)
AT (1) ATE297895T1 (zh)
AU (1) AU779063B2 (zh)
BR (1) BR0016172A (zh)
CA (1) CA2392566A1 (zh)
CO (1) CO5080771A1 (zh)
CZ (1) CZ20022352A3 (zh)
DE (1) DE60020883T2 (zh)
DK (1) DK1244625T3 (zh)
ES (1) ES2243335T3 (zh)
GC (1) GC0000214A (zh)
HR (1) HRP20020467A2 (zh)
HU (1) HUP0203735A3 (zh)
IL (2) IL149622A0 (zh)
JO (1) JO2281B1 (zh)
MA (1) MA26849A1 (zh)
MX (1) MXPA02005240A (zh)
MY (1) MY128003A (zh)
NO (1) NO322910B1 (zh)
NZ (1) NZ518888A (zh)
PE (1) PE20010960A1 (zh)
PL (1) PL364814A1 (zh)
PT (1) PT1244625E (zh)
RU (1) RU2270193C2 (zh)
TW (1) TWI276629B (zh)
UY (1) UY26470A1 (zh)
WO (1) WO2001042215A1 (zh)
YU (1) YU40502A (zh)
ZA (1) ZA200203762B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
NZ524122A (en) 2000-08-18 2005-02-25 Ajinomoto Kk Phenylalanine derivatives useful as pharmaceutical agents
JP4895067B2 (ja) * 2000-09-29 2012-03-14 味の素株式会社 新規フェニルアラニン誘導体
JP4452899B2 (ja) 2001-12-13 2010-04-21 味の素株式会社 新規フェニルアラニン誘導体
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2005061466A1 (ja) 2003-12-22 2005-07-07 Ajinomoto Co., Inc. 新規フェニルアラニン誘導体
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
CN101006097B (zh) * 2004-08-16 2012-07-11 默沙东公司 Vla-4拮抗剂
JP4784224B2 (ja) 2004-09-24 2011-10-05 味の素株式会社 糖鎖転移方法および糖鎖転移酵素
US8410115B2 (en) * 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
AR060901A1 (es) * 2006-05-12 2008-07-23 Jerini Ag Compuestos heterociclicos para la inhibicion de integrinas y uso de estos
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
MX2010011145A (es) 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.
EP2456747B1 (de) * 2009-07-23 2014-06-25 Bayer CropScience AG Verfahren zur Herstellung von Alkoxyenonen und Enaminoketonen
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
KR20140127234A (ko) * 2012-01-27 2014-11-03 에프. 호프만-라 로슈 아게 Ｖｌａ-4 발현 세포로의 표적화된 전달을 위한 인테그린 안타고니스트 접합체
KR102271179B1 (ko) * 2013-06-11 2021-07-01 셀진 인터내셔널 Ii 에스에이알엘 신규의 glp-1 수용체 조절제
JP6820282B2 (ja) 2016-02-05 2021-01-27 Ｅａファーマ株式会社 スルホンアミド誘導体及びそれを含有する医薬組成物
EP3873897B1 (en) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
PL3873605T3 (pl) 2018-10-30 2025-03-03 Gilead Sciences, Inc. Związki hamujące integrynę alfa4beta7
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
JP2001517245A (ja) * 1997-05-29 2001-10-02 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのビアリールアルカン酸類
CA2291778A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
AU3260399A (en) * 1998-02-26 1999-09-15 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
GB9811159D0 (en) * 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
ES2220140T3 (es) * 1998-12-22 2004-12-01 Tanabe Seiyaku Co., Ltd. Inhibidores de la adhesion mediada de celulas por alfa 4 beta 1 (a4b1).
DE60021251D1 (de) * 1999-01-22 2005-08-18 Elan Pharm Inc Multizyklische verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion

Also Published As

Publication number Publication date
HUP0203735A2 (hu) 2003-03-28
JP2003516392A (ja) 2003-05-13
MXPA02005240A (es) 2002-11-07
HRP20020467A2 (en) 2004-04-30
CA2392566A1 (en) 2001-06-14
EP1244625B1 (en) 2005-06-15
IL149622A0 (en) 2002-11-10
GC0000214A (en) 2006-03-29
EP1244625A1 (en) 2002-10-02
MY128003A (en) 2007-01-31
WO2001042215A1 (en) 2001-06-14
TWI276629B (en) 2007-03-21
AU779063B2 (en) 2005-01-06
ES2243335T3 (es) 2005-12-01
KR20020060256A (ko) 2002-07-16
YU40502A (sh) 2005-03-15
AR031083A1 (es) 2003-09-10
RU2270193C2 (ru) 2006-02-20
JO2281B1 (en) 2005-09-12
JP2008094842A (ja) 2008-04-24
DK1244625T3 (da) 2005-10-10
CN1196682C (zh) 2005-04-13
CO5080771A1 (es) 2001-09-25
HUP0203735A3 (en) 2005-03-29
NZ518888A (en) 2004-02-27
IL149622A (en) 2006-12-10
NO20022650L (no) 2002-06-05
AU2163901A (en) 2001-06-18
CN1402709A (zh) 2003-03-12
CZ20022352A3 (cs) 2003-05-14
NO20022650D0 (no) 2002-06-05
NO322910B1 (no) 2006-12-18
DE60020883D1 (de) 2005-07-21
ATE297895T1 (de) 2005-07-15
PE20010960A1 (es) 2001-09-22
KR100492111B1 (ko) 2005-06-01
HK1053470A1 (zh) 2003-10-24
MA26849A1 (fr) 2004-12-20
PL364814A1 (en) 2004-12-13
DE60020883T2 (de) 2006-03-23
PT1244625E (pt) 2005-09-30
UY26470A1 (es) 2001-05-31
BR0016172A (pt) 2002-08-20

Similar Documents

Publication Publication Date Title
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
ZA200200477B (en) 2-pyrazolin-5-ones.
EG24361A (en) 4-pyrimiding1-n-acy1.l.phenlalanines
ZA200000894B (en) 4-Phenyl-pyridine derivatives.
ZA200201055B (en) Amino-triazolopyridine derivatives.
ZA996185B (en) Sulfanylsilanes.
ZA200005136B (en) Dihydropyrimides.
ZA200202537B (en) Pour-on-formulations.
ZA200201829B (en) New phenylpiperazines.
ZA200109595B (en) 13-methyl-erythromycin derivatives.
ZA200203762B (en) 4-pyridinyl-IN-acyl-L-phenylalanines.
ZA200108968B (en) New compounds.
ZA992443B (en) Hydroxy-methyl-hexanones.
ZA993123B (en) Trisresorcinyltriazines.
ZA995325B (en) Methylcyclotetradec-5-en-1-ones.
ZA200201276B (en) 3-Amino-2-phenyl-propane derivatives.
MXPA02000261A (es) Aminoindanos novedosos.
GB0029720D0 (en) I.S machine7544232001
MXPA01011285A (es) Derivados de tio-oxindol.
ZA200204581B (en) Nitro-sulfobenzamides.
ZA200005361B (en) Positioning arrangement.
MXPA01013157A (es) Perfil.
ZA200007026B (en) Acart.
ZA200007821B (en) Hidroponiese Plantproduksiestelsel.
ZA200203458B (en) Diaryl-enynes.